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Rationale: Augmentation therapy with serotonin-1A (5-HT1A) receptor partial agonists
has been suggested to improve cognitive impairment in patients with schizophrenia.
Decreased activity of prefrontal cortex may provide a basis for cognitive deficits of
the disease. Lactate plays a significant role in the supply of energy to the brain, and
glutamatergic neurotransmission contributes to lactate production.
Objectives and methods: The purposes of this study were to examine the effect of
repeated administration (once a daily for 4 days) of tandospirone (0.05 or 5mg/kg) on
brain energy metabolism, as represented by extracellular lactate concentration (eLAC) in
the medial prefrontal cortex (mPFC) of a rat model of schizophrenia.
Results: Four-day treatment with MK-801, an NMDA-R antagonist, prolonged eLAC
elevation induced by foot-shock stress (FS). Co-administration with the high-dose
tandospirone suppressed prolonged FS-induced eLAC elevation in rats receiving MK-801,
whereas tandospirone by itself did not affected eLAC increment.
Conclusions: These results suggest that stimulation of 5-HT1A receptors ameliorates
abnormalities of energy metabolism in the mPFC due to blockade of NMDA receptors.
These findings provide a possible mechanism, based on brain energy metabolism,
by which 5-HT1A agonism improve cognitive impairment of schizophrenia and related
disorders.
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INTRODUCTION
Disturbances of cognitive function, evaluated by psychologi-
cal and neurophysiological methods, have been shown to pre-
dict social outcome in patients with schizophrenia (Meltzer and
McGurk, 1999; McGurk andMeltzer, 2000). There is much atten-
tion to the role of psychotropic compounds acting on serotonin
(5-HT) receptors in ameliorating cognitive deficits of the dis-
ease. Among the 5-HT receptor subtypes, the 5-HT1A receptor
is attracting particular interests as a potential target for enhanc-
ing cognition (Newman-Tancredi and Albert, 2012; Ohno et al.,
2012; Sumiyoshi and Higuchi, 2013; Sumiyoshi et al., 2013).
It is reported that adjunctive treatment with selective 5-HT1A
receptor (partial) agonists, e.g., tandospirone or buspirone, was
associated with improvements in some types of cognitive func-
tion in patients with schizophrenia (Sumiyoshi et al., 2001b,
2007; Sumiyoshi and Higuchi, 2013). These observations pro-
vide the basis for the ability of 5-HT1A receptor stimulation to
enhance cognition, a therapeutic approach that have promoted
the development of novel antipsychotic drugs (Sumiyoshi, 2013;
Sumiyoshi et al., 2013).
The development of animal models of schizophrenia is impor-
tant to clarify the pathophysiology of the illness and facilitate
the development of novel therapeutics. Non-competitive antago-
nists at the N-methyl-D-asparate receptor (NMDA-R) have been
shown to induce schizophrenia-like symptoms, i.e., positive and
negative symptoms, as well as cognitive dysfunction in normal
subjects (Jentsch and Roth, 1999). Numerous studies reported
that NMDA-R antagonists, such as phencyclidine (PCP), MK-801
and ketamine, produce hyperlocomotion, stereotypy, informa-
tion processing deficits, impairments of cognitive functions and
social interactions, behavioral changes reminiscent of symptoms
of schizophrenia (Breese et al., 2002; Moghaddam and Jackson,
2003; Bubenikova-Valesova et al., 2008; Jones et al., 2011).
Four-day treatment with MK-801 changed behaviors and
expression of NMDA-Rs in a way that mimicked chronic treat-
ment (Bubenikova-Valesova et al., 2010). Especially, prepulse
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inhibition (PPI) was impaired, while locomotion was decreased
(Bubenikova-Valesova et al., 2010). PPI deficits are one of the
most widely used neurophysiological markers of the patho-
physiology of schizophrenia, and have been suggested to repre-
sent an aspect of cognitive deficits (Geyer, 2006; Singer et al.,
2013). Especially, a specific correlative link between working
memory and PPI has been reported in rodents (Singer et al.,
2013). On the other hand, the mPFC was the target brain
region in the current study because our aim was to clarify
the mechanisms underlying cognitive enhancement by 5-HT1A
receptor stimulation. Functional abnormality of the frontal cor-
tex has been associated with negative symptoms and cognitive
deficits (Volk and Lewis, 2002). Specifically, performance on
the cognitive tasks governed by the prefrontal cortex (PFC),
e.g., working memory and executive function, has been consis-
tently reported in patients with schizophrenia (Tamminga et al.,
1992; Volz et al., 1999; Hazlett et al., 2000; Ragland et al.,
2007).
Since the proposal of the astrocyte-neuron lactate shut-
tle (ANLS) hypothesis (Pellerin and Magistretti, 1994), lactate
has been found to play a crucial role in energy metabolism
in the brain (Tsacopoulos and Magistretti, 1996; Pellerin and
Magistretti, 2012). According to this hypothesis, lactate is pro-
duced in a neural activity-dependent and glutamate-mediated
manner in astrocytes, and is transferred to active neurons
(Pellerin et al., 1998, 2007; Pellerin, 2003; Uehara et al., 2008).
Moreover, it has been shown that lactate is a primary substrate for
energy metabolism in the brain of humans (Smith et al., 2003)
or rodents (Wyss et al., 2011) under working conditions if both
lactate and glucose is sufficiently available, as demonstrated by
in vivo studies (Wyss et al., 2011).
Whether or not abnormality of lactate metabolism exists in the
brain of schizophrenia patients remains to be discussed. A post-
mortem study reports altered transcription of genes in a large
number of metabolic pathways and increased lactate levels in
the PFC of patients with schizophrenia (Prabakaran et al., 2004).
However, another report argued that these changes are associated
with decreased pH, and are possibly related to antipsychotic treat-
ment rather than a primary metabolic abnormality (Halim et al.,
2008).
In this study, we investigated the effect of repeated (four
consecutive days) administration of MK-801, a non-competitive
NMDA-R antagonist, on energy metabolism indicated by extra-
cellular lactate concentration (eLAC) in the medial prefrontal
cortex (mPFC) of rats using microdialysis technique. Then, we
determined whether co-administration of low and high doses
(0.05 or 5mg/kg) tandospirone affect lactate metabolism in the
MK-801 treated animals.
MATERIALS AND METHODS
ANIMALS
Adult male Wistar rats (Japan SLC Inc., Hamamatsu, Japan)
weighing 280–300 g (8 weeks postnatal) for microdialysis exper-
iments were housed 4–5 in a standard cage at 24 ± 2◦C under a
12-h light (07:00–19:00 h) 12-h dark cycle. The procedures com-
plied with the National Institutes of Health guide for the care and
use of Laboratory animals. All experiments were reviewed and
approved by the Committee of Animal Research, University of
Toyama.
DRUGS
Tandospirone was provided from Dainippon Sumitomo
Pharmaceuticals (Tokyo, Japan).
The treatment regimen with MK-801 (dizocilpine, 0.1mg/kg,
Sigma-Aldrich, St. Louis, MO) and/or tandospirone was based on
a previous report (Bubenikova-Valesova et al., 2010) with minor
modifications. First, to evaluate the effect of 4 days treatment with
MK-801 on eLAC in the mPFC, rats received an intraperitoneal
(i.p.) injection of MK-801 (0.1mg/kg) at a volume of 2ml/kg
(MK-801 group, n = 6), or the equal volume of saline (saline
group, n = 5) once daily for 4 days. Second, to access the effect of
tandospirone on FS-induced eLAC changes, rats received a sub-
cutaneous (s.c.) injection of tandospirone at 0.05mg/kg (low-T)
or 5.0mg/kg (high-T) at a volume of 2ml/kg or the equal volume
of saline. This yielded the following 6 groups: saline-saline group
(n = 5); saline-low-T group (n = 5); saline-high-T group (n =
5); MK-801-saline group (n = 5); MK-801-low-T group (n–5);
MK-801-high-T group (n = 5). The last injection was adminis-
tered 10min before the start of foot-shock (FS) stress (Figure 1).
SURGERY
Extracellular lactate concentrations were measured by in vivo
microdialysis technique with an enzyme reactor/fluorometric
detector according to the method previously reported (Uehara
et al., 2003, 2005, 2006, 2007a). The animals were anesthetized
with pentobarbital sodium (Nembutal, Abbott Laboratories, IL,
USA) (40mg/kg, i.p.), and were mounted on a stereotaxic appa-
ratus. A dialysis probe (molecular weight cutoff 10,000; 200μm
in outer diameter) was implanted into the left mPFC accord-
ing to the atlas of Paxinos and Watson (1998), and was secured
with skull screws and dental acrylate. The exposed tip length of
the probe was 1.5mm. Coordinates were A 3.2mm, L 0.6mm, V
5.2mm from bregma for the mPFC. Following the surgery, the
rats were housed in individual cages with free access to food and
water.
FIGURE 1 | Schematic representation of the experimental protocol for
microdialysis experiments. Upper parts in each figure reveals drug
treatment for 4 days and lower parts time course in the 4th day (experiment
day).
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Forty-two to 48 h after surgery, the dialysis experiment was
carried out on the freely moving rats. Microdialysis experiments
were performed between 08:00 and 16:00. Artificial CSF (con-
sisting of 147mmol/l NaCl, 3mmol/l KCl, 1.2mmol/l CaCl2,
1.2mmol/l MgSO4, 0.4mmol/l NaH2PO2, pH 7.40) was perfused
at a rate of 5.0μl/min into the dialysis probe. The dialysates
were mixed on-line with an enzyme solution containing L-
lactate dehydrogenase and NAD+ in a T-tube. The enzyme
solution consisted of 5.0μg/ml LDH (L-Malate: NAD oxidore-
ductase, E.C.1.1.1.27; isolated from pig heart, specific activity
ca.300U/mg; Roche Diagnostics GmbH, Mannheim, Germany)
and 0.5mmol/l NAD+ (Roche Diagnostics GmbH, Mannheim,
Germany) in a carbonate buffer (62.5mmol/l, adjusted to pH 9.4
with NaOH). The solution was pumped using a Model 22 micro-
dialysis pump (Harvard Apparatus, Inc. Massachusetts, USA)
at the flow rate of 20μl/min. The mixture from the T-tube
was passed for 20min reaction before reaching a fluorometer
equipped with a 12μl flow-cell (Shimazu RF-530, Kyoto, Japan).
During transport to the fluorometer, lactate was enzymatically
oxidized, and the fluorescence of the formed nicotinamid
adenosine dinucleotide diphosphate (NADH) was continuously
measured with excitation at 340 nm and emission at 450 nm.
A standard solution of 100μmol/l lactate was used for calibration.
FOOT-SHOCK STRESS
Foot-shock (FS) stress was administered using a plastic commu-
nication box (CB5, MATYS, Toyama, Japan), according to the
method reported previously (Uehara et al., 2012a). The box (L
51 × W 51 × H 40 cm) was equipped with a grid floor composed
of stainless steel rods (6-mm in diameter) placed 16mm apart.
The box was subdivided into nine compartments (17 × 17 cm) by
transparent plastic walls. In this study, we used 4 compartments
areas (34 × 34 cm) for the field of free moving and FS admin-
istration. The communication box was connected to a shock-
generator (MSG-001, MATYS, Toyama, Japan) and a timer-box
(MTB-001, MATYS, Toyama, Japan) to deliver FS as described
below. Each FS session consisted of a scramble shock of 0.3mA
for 5 s administered every 30 s for 10min.
At the end of the experimental sessions, all rats were deeply
anesthetized with pentobarbital sodium, and were sacrificed by
decapitation. The position of dialysis probes was verified micro-
scopically for all rats.
PRESENTATION OF THE RESULTS AND STATISTICS
Data were analyzed by analysis of variance (ANOVA) using SPSS
software (version 19.0 J for Mac; IBM, Tokyo, Japan).
Lactate levels in the dialysates are expressed asμmol/l cal-
culated by a standard solution of 100μmol/l lactate. The aver-
age of the eLAC during the period preceding the last injection
(four measurements performed every 5min) was used as the
basal concentrations of lactate. To access the effects of MK-
801 and tandospirone on basal lactate levels, two-way ANOVA
were carried out with MK-801 treatment (saline, MK-801) as
one factor and tandospirone treatment (saline, low-T, high-T)
as the second factor. Data from MK-801 administration was
analyzed using repeated measure ANOVA. MK-801 treatment
(saline,MK-801). Time was treated as repeatedmeasures variable.
Data from FS stress procedures were analyzed using two-way
repeated measure ANOVA. MK-801 treatment (saline, MK-801)
and tandospirone treatment (saline, low-T, high-T) were treated
as between-group variable. Time was treated as repeatedmeasures
variable. Thereafter, two-way repeated measures ANOVA were
performed for each group. Data were analyzed by Kruskal-Wallis
test at each time point, and statistical significance was further
examined by Mann-Whitney test for multiple comparisons.
To compare the results of with and without FS experiments,
we analyzed total increase amount of lactate after last injection
in each groups calculated by sum of eLAC data subtractiong the
basal concentration of eLAC from eLAC concentration at each
time point (from time 0 to time 110). These data were ana-
lyzed using one-factor ANOVA (8 groups; saline group without
FS, MK-801 group without FS, saline-saline group, saline-low-T
group, saline-high-T group, MK-801-saline group, MK-801-low-
T group, MK-801-high-T group) followed by post-hoc Bonferroni
test. A probability (P) of less than 0.05 was considered to be
significant.
RESULTS
BASAL LACTATE LEVELS
The basal concentrations of lactate in 8 groups (with or without
FS experiments) were shown in Table 1. There were no significant
interaction [F(2,35) = 0.48, P = 0.62], main effect of MK-801
treatment [F(1,35) = 0.48, P = 0.49] and tandospirone treatment
[F(2,35) = 0.19, P = 0.83].
EFFECT OF MK-801 ADMINISTRATION ON eLAC
Repeated measures ANOVA demonstrated that MK-801 treat-
ment increased eLAC in the mPFC [MK-801 x time interaction,
F(22,198) = 5.73, P < 0.001]. MK-801 administration increased
eLAC from 35 to 45min (Figure 2).
EFFECT OF MK-801 AND TANDOSPIRONE COMBINATION ON
FS-INDUCED eLAC ELEVATION
Two-way ANOVA revealed that both MK-801 treatment x
time interaction and tandospirone treatment x time interac-
tion were significant [F(22,528) = 10.31, P < 0.001; F(44,528) =
5.65, P < 0.001; respectively]. These results indicated that
Table 1 | The basal concentrations of lactate in dailysates in each
grop.
Foot-shock Foot-shock
stress(−) stress (+)
Saline Tandospirone
Low (0.05 High (5.0
mg/kg) mg/kg)
Saline 50.92 ± 4.99 47.26 ± 4.99 51.46 ± 2.44 50.44 ± 2.63
MK-801 50.47 ± 1.20 47.62 ± 5.12 48.23 ± 2.5 43.96 ± 7.26
The basal concentrations of lactate in daily sates were presented the average
of the eLAC during the period preceding the last injection (four measurements
performed every 5min). Values are expressed as mean ± SE,µmol/L.
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FIGURE 2 | Time course of the effect of 4 days treatment of MK-801 on
the extracellular lactate concentrations (eLAC) in the medial prefrontal
cortex. Rats were treated with saline (saline group, n = 6; open circle) or
MK-801 (MK-801 group, n = 5; closed circle). Lactate levels in the dialysates
are expressed asμmol/l calculated by a standard solution of 100μmol/l
lactate. Data are mean ± s.e.m. The arrow indicates the timing of the last
injection. Asterisk showed p < 0.05 vs. saline group in each time point.
MK-801 treatment produced prolonged FS-induced eLAC eleva-
tion (Figure 3A), and that co-administration with tandospirone
(5.0mg/kg) abolished this change (Figure 3C) but not tan-
dospirone (0.05mg/kg) (Figure 3B). At each time point data
analysis, there were significant eLAC differences betweenMK-801
and saline group at 70, 75, and 85min after the last injec-
tion in low-dose tandospirone administration group (Figure 3B),
whereas no significant differences at each time point in saline or
high-dose tandospirone administration group (Figures 3A,C).
EFFECT OF TANDOSPIRONE ON FS-INDUCED eLAC ELEVATION IN
SALINE TREATMENT GROUP
Two-way ANOVA revealed no significant tandospirone treat-
ment x time interaction [F(44,264) = 1.90, P = 0.08]. This result
demonstrated that 4 days treatment with tandospirone did
not affected on FS-induced eLAC elevation in the mPFC
(Figures 3A,C).
TOTAL INCREASE AMOUNT OF LACTATE AFTER LAST INJECTION
One-factor ANOVA demonstrated significant differences among
8 groups [F(7,33) = 6.01, P < 0.001]. Post-hoc Bonferroni test
showed significant differences between saline group without FS
and MK-801-saline group, saline group without FS and MK-
801-low-T group, MK-801 group without FS and MK-801-low-T
group, saline-high-T group andMK-801-low-T group (Figure 4).
These results indicated that repeated MK-801 administration by
itself have a temporary effect on eLAC changes in the mPFC.
DISCUSSION
This study obtained results showing; (1) acute treatment with
MK-801 in the 4th day increased eLAC to around 65μmol/L
above the base line level, and 4-day treatment with MK-801 pro-
longed eLAC elevation induced by FS in the mPFC, whereas
its effect was temporary, and (2) co-administration with high-
dose tandospirone abolished the effect of MK-801 treatment on
prolonged eLAC elevation.
FIGURE 3 | Effect of tandospirone on foot-shock stress-induced
increment of the extracellular lactate concentrations (eLAC) in the
medial prefrontal cortex in rats treated with (A) saline (saline-saline
group, n = 5; MK-801-saline group, n = 5), (B) tandospirone 0.05mg/kg
(saline-low-T group, n = 5; MK-801-low-T group, n-5) and (C) 5.0mg/kg
tandospirone (saline-high-T group, n = 5; MK-801-high-T group, n = 5).
Rats were simultaneously treated with saline (open circle) or MK-801
(closed circle), respectively. Lactate levels in the dialysates are expressed
asμmol/l calculated by a standard solution of 100μmol/l lactate. Data are
mean ± s.e.m. The arrow indicates the timing of the last injection.
Foot-shock is indicated by solid bars. Asterisk showed p < 0.05 vs. saline
group in each time point.
Four-day treatment with MK-801 at the young adult stage
resulted in increasing of eLAC after FS (Figure 3), while repeated
MK-801 treatment by itself may have little effect on total increase
amount of lactate (Figure 4). This finding is consistent with a
postmortem study reporting an increase in lactate levels in the
PFC of patients with schizophrenia (Prabakaran et al., 2004).
Possible mechanisms include glutamatergic neurotransmissions,
because eLAC has been suggested to be linked to them (Uehara
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FIGURE 4 | Total increase of lactate after injection (from time 0 to time
110min) calculated by sum of (each eLAC concentration—basal
concentration of eLAC). Basal concentration of eLAC is the average of
eLAC during the period preceding the last injection (four measurements
performed every 5min). Asterisk showed p < 0.05 between groups.
et al., 2008). Thus, glutamate taken up into astrocytes through
glutamate transporters (GLT) after synaptic release stimulates
glycolysis and lactate production in astrocytes. In this process,
glutamate uptake into astrocytes and the resulting increase in
intracellular Na+ have been identified as a key signal cou-
pling excitatory neural activity to increased glucose utilization
(Magistretti et al., 1999; Chatton et al., 2000). Moreover, glu-
tamate stimulates aerobic glycolysis in astrocytes (Pellerin and
Magistretti, 1994). This metabolic action of glutamate is medi-
ated by glutamate transporters, and involves the activity of
Na+/K+ ATPase in astrocytes (Pellerin and Magistretti, 1997).
In fact, local perfusion of the glutamate reuptake inhibitor dihy-
drokainate (DHK) has been reported to attenuated FS-induced
increment eLAC in the mPFC (Uehara et al., 2007b). On the
other hand, activation of NMDA-Rs increases eLAC in the mPFC
of rodents (Kuhr and Korf, 1988; Schasfoort et al., 1988). These
authors reported that infusion of NMDA (10mM) or kainic acid
(0.5mM) for 1min resulted in an transient increase in extracel-
lular lactate concentrations, which lasted several minutes longer
than the drug administration period. Furthermore, MK-801, as
well as other NMDA-R antagonists, may produce disinhibition of
glutamate and γ-aminobutyric acid (GABA) or other inhibitory
inputs to the glutamate-containing neurons, thereby enhancing
the firing rate of these glutamatergic neurons. Such disinhibition
may occur locally at the PFC and/or at regions with ascend-
ing glutamatergic projections to the PFC (Moghaddam et al.,
1997). These findings suggest that systemic MK-801 administra-
tion increases glutamate levels in the synaptic cleft, and prolong
eLAC elevation in the mPFC.
We previously reported that the long-term effect of transient
MK-801 treatment in neonatal periods on lactate metabolism
in the mPFC of young adult rats (Uehara et al., 2012a).
According to the study, transient MK-801 treatment in neonatal
stage suppressed FS stress-induced eLAC elevation in the mPFC
without changes in the basal levels. Moreover, Neonatal NMDA-R
blockade-induced attenuation of lactate response was ameliorated
by 5-HT1A receptor stimulations for 14 days in young adult stage.
These findings were completely opposite effect to young adult rats
treated repeatedly withMK-801 in this study. It is possible that the
opposite effect on eLAC reactions to FS was based on the timing
of MK-801 administration. Administration of NMDA-R antago-
nists in the late fetal or early postnatal periods enhances neuronal
apoptosis (Ikonomidou et al., 1999; Beninger et al., 2002; Harris
et al., 2003). PCP administration in the neonatal stage has been
shown to induce apoptotic changes, gliosis (Wang et al., 2001,
2003) and to reduce spine density (Nakatani-Pawlak et al., 2009)
in the frontal cortex. These findings suggest that neonatal block-
ade of NMDA-R produced morphological changes and then
reduction of the production source and/or dysfunction of the
astrocyte-neuron lactate shuttle system. Furthermore, neonatal
blockade of the NMDA-R led to up-regulation of the NR1 recep-
tor subunit in the frontal cortex (Wang et al., 1999, 2001; Du Bois
and Huang, 2007). We reported neonatal MK-801 administration
reduced the number of parvalbumin-positive GABA interneurons
in the mPFC (Uehara et al., 2012b,c). Based on these findings,
it is possible that neonatal MK-801 treatment decreased gluta-
mate release in the mPFC, leading to the reduction of eLAC. On
the other hand, low doses of MK-801 (<3mg/kg) induced tran-
sient vacuolization in cortical layers III and IV of adult rodents,
which was maximal 12 h after the drug and then gradually disap-
peared during the next 12–18 h (Olney et al., 1989). Therefore, it
is assumed that the dose of MK-801 (0.1mg/kg) in this study may
have produced little morphological changes.
Co-administration of tandospirone, a 5-HT1A receptor par-
tial agonist, attenuated prolonged eLAC elevation in the mPFC
induced by MK-801 (Figure 3C). Acute treatment with tan-
dospirone has been shown to attenuate the eLAC elevation by
FS (Uehara et al., 2006). 5-HT1A agonists have been shown to
inhibit potassium-evoked glutamate release in vitro (Mauler et al.,
2001) while MK-801 increases glutamate in the mPFC in vivo
(Lopez-Gil et al., 2009). 5-HT1A receptors are also involved in the
modulation of excitatory glutamatergic neurotransmission, since
their activation reduces NMDA-mediated currents in PFC neu-
rons (Zhong et al., 2008). Moreover, 5-HT1A agonists block the
MK-801-induced increase in 5-HT concentrations in the mPFC
(Lopez-Gil et al., 2009). Therefore, it is possible that tandospirone
shortens the period of eLAC elevation through inhibition of
glutamate release and serotonergic transmissions.
Unexpectedly, 4-day treatment with tandospirone
(5.0mg/kg/day, i.p.) did not suppress FS-induced eLAC ele-
vation in the mPFC of saline-treated rats, in contrast to our
previous observation with tandospirone at 2.0mg/kg (Uehara
et al., 2006). Moreover, the drug at 0.1, 1.0, or 5.0mg/kg attenu-
ated FS-induced eLAC increment (Uehara et al., 2012a), although
last injection was 24 h before eLAC measurement.
Chronic administration of 5-HT1A agonists has been shown
to desensitize 5-HT1A auto receptors in the raphe nucleus, but
not frontal cortex (Sim-Selley et al., 2000; Hensler et al., 2003).
After sustained treatment with these agents, 5-HT neurons in the
raphe nucleus gradually recover their baseline firing rates and
become normalized in 14 days (Blier and De Montigny, 1987;
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Godbout et al., 1991; Blier and Ward, 2003). Treatment with tan-
dospirone for 2 days (10mg/kg/day, s.c.), markedly reduces the
firing activity of 5-HT neurons of the dorsal raphe, followed by
partial recovery after 7 days and complete recovery after 14 days
of tandospirone administration (Godbout et al., 1991). Therefore,
4-day treatment with tandospirone may decrease 5-HT release
into the synaptic cleft in the mPFC. On the other hand, postsy-
naptic 5-HT1A receptor stimulation inhibits NMDA antagonist-
induced glutamate release in the mPFC (Calcagno et al., 2006)
and potassium-evoked lactate release in vitro (Mauler et al., 2001).
Taken together, the discrepant results in our reports, above, may
be explained by the balance between autoreceptor desensitization
in the raphe nucleus and intensity of stimulation of post-synaptic
receptors in the mPFC.
In summary, stimulation of 5-HT1A receptors normal-
ized changes of lactate metabolism in the mPFC of rats
exposed to repeated NMDA-R injections. Our findings pro-
vide a possible mechanism underlying the clinical observations
that tandospirone improves cognitive deficits in patients with
schizophrenia (Sumiyoshi et al., 2000, 2001a,b). Importantly,
lactate metabolism may provide a novel probe for the develop-
ment of therapeutics for cognitive impairment of schizophrenia
(Uehara and Sumiyoshi, 2013).
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